{"protocolSection": {"identificationModule": {"nctId": "NCT00159263", "orgStudyIdInfo": {"id": "BU-039-0005"}, "organization": {"fullName": "Imperial College London", "class": "OTHER"}, "briefTitle": "Effect of Symbicort on GR Localisation in Asthma", "officialTitle": "Effect of Symbicort on GR (Glucocorticoid Receptor) Translocation in Induced Sputum in Comparison With Budesonide, Formoterol and Placebo. A Single Dose Exploratory Study in Patients With Mild Asthma"}, "statusModule": {"statusVerifiedDate": "2019-09", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2004-11", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2006-11", "type": "ACTUAL"}, "completionDateStruct": {"date": "2006-11", "type": "ACTUAL"}, "studyFirstSubmitDate": "2005-09-08", "studyFirstSubmitQcDate": "2005-09-08", "studyFirstPostDateStruct": {"date": "2005-09-12", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2019-07-08", "resultsFirstSubmitQcDate": "2019-09-24", "resultsFirstPostDateStruct": {"date": "2019-09-27", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2019-09-24", "lastUpdatePostDateStruct": {"date": "2019-09-27", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Imperial College London", "class": "OTHER"}, "collaborators": [{"name": "AstraZeneca", "class": "INDUSTRY"}]}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "To investigate a possible interaction between formoterol and budesonide on GR-translocation and to compare the effect of different doses of Symbicort (80/4.5 and 2x80/4.5 mcg) with the effect of budesonide (200 mcg and 800 mcg) on GR translocation, and to investigate the effect of the study drugs on exhaled NO (bronchial and alveolar fraction.", "detailedDescription": "Combination therapy with inhaled corticosteroids (ICS) and long-acting \u03b2(2)-adrenergic agonists (LABA) is reported to have superior effects on controlling asthma symptoms to ICS alone; however, there is no molecular-based evidence to explain the clinical effects. Here, the effect of the ICS/LABA combination was compared with ICS on glucocorticoid receptor (GR) activation in sputum macrophage.\n\nIn a randomised, double-blind cross-over placebo-controlled 6-visit study, 10 patients with mild asthma were given placebo, formoterol (Oxis(\u00ae) 12 \u03bcg), budesonide (Pulmicort(\u00ae) 200 \u03bcg :BUD200, or 800 \u03bcg :BUD800), or budesonide/formoterol combination (Symbicort(\u00ae)) as a single 100/6 \u03bcg (SYM100) or double 200/12 \u03bcg (SYM200) dose. Sputum macrophages were separated by plate adhesion from induced sputum. GR binding to the glucocorticoid-response elements on oligonucleotides (GR-GRE binding) was evaluated by ELISA. mRNA expression of MAP-kinase phosphatase (MKP)-1 and IL-8 were measured by quantitative RT-PCR."}, "conditionsModule": {"conditions": ["Asthma"], "keywords": ["Asthma", "Glucocorticoid", "Long-acting beta2-adrenoceptor", "Inhaled corticosteroids"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["NA"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "CROSSOVER", "primaryPurpose": "BASIC_SCIENCE", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 10, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "placebo", "interventionNames": ["Drug: Placebos"]}, {"label": "Formoterol", "type": "EXPERIMENTAL", "description": "Oxis(\u00ae) 12 \u03bcg", "interventionNames": ["Drug: Formoterol Inhalant Powder"]}, {"label": "Budesonide low dose", "type": "EXPERIMENTAL", "description": "Pulmicort(\u00ae) 200 \u03bcg", "interventionNames": ["Drug: Budesonide Powder"]}, {"label": "Budesonide high dose", "type": "EXPERIMENTAL", "description": "Pulmicort(\u00ae) 800 \u03bcg", "interventionNames": ["Drug: Budesonide Powder"]}, {"label": "Budesonide/formoterol combination single", "type": "EXPERIMENTAL", "description": "single 100/6 \u03bcg SYM100", "interventionNames": ["Drug: Budesonide and Formoterol Product"]}, {"label": "Budesonide/formoterol combination double", "type": "EXPERIMENTAL", "description": "double 200/12 \u03bcg SYM200", "interventionNames": ["Drug: Budesonide and Formoterol Product"]}], "interventions": [{"type": "DRUG", "name": "Placebos", "description": "Dry powder inhaler", "armGroupLabels": ["Placebo"]}, {"type": "DRUG", "name": "Formoterol Inhalant Powder", "description": "12ug", "armGroupLabels": ["Formoterol"], "otherNames": ["Oxis"]}, {"type": "DRUG", "name": "Budesonide Powder", "description": "Inhaler", "armGroupLabels": ["Budesonide high dose", "Budesonide low dose"], "otherNames": ["Pulmicort"]}, {"type": "DRUG", "name": "Budesonide and Formoterol Product", "description": "Combination Inhaler, Symbicort", "armGroupLabels": ["Budesonide/formoterol combination double", "Budesonide/formoterol combination single"], "otherNames": ["Combination Inhaler, Symbicort"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Changes in GR-GRE Binding", "description": "The GR-GRE binding is the glucocorticoid receptor (GR) DNA binding affinity. GR-GRE activity as assed by enzyme-immunosorbent assay", "timeFrame": "1-2h"}, {"measure": "Changes in MKP-1 mRNA", "description": "Changes in MKP-1 mRNA measured by PCR", "timeFrame": "1-2h"}, {"measure": "IL8 mRNA", "description": "Measured by PCR", "timeFrame": "1-2h"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Patients with mild steroid-na\u00efve asthma (ATS criteria) of either sex with FEV1 \\>70 % pred\n* Able to produce sputum after sputum induction\n* Exhaled NO (flow 50 ml/s) \u2265 20 ppb\n* Written informed consent\n\nExclusion Criteria:\n\n* Current upper respiratory tract infections\n* Use of inhaled and/or oral GCS within 4 weeks prior to visit 1\n* Treatment with antileukotrienes, theophylline, tiotropium and ipratropium within 2 weeks prior to screening visit\n* Hypersensitivity to any of the investigational drugs or lactose\n* Use of any beta blocking agent (including eye-drops)\n* Women who are pregnant, breast-feeding or planning a pregnancy during the study. Women must be postmenopausal (at least one year must have passed after the last menstruation), surgically sterile or using acceptable contraceptives, as judged by the investigator\n* Any significant disease or disorder (e.g. cardiovascular, pulmonary (other than asthma), gastrointestinal, liver, renal, neurological, musculoskeletal, endocrine, metabolic, malignant, psychiatric, major physical impairment) which, in the opinion of the investigator, may either put the subject at risk because of participation in the study, or may influence the results of the study, or the subjects ability to participate in the study\n* Inability to tolerate temporary withdrawal of bronchodilatory therapy\n* Subjects not considered capable, as judged by the investigator, of following instructions of the study, e.g. because of a history of alcohol or drug abuse or any other reason\n* Previous randomization in this study", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "21 Years", "maximumAge": "60 Years", "stdAges": ["ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Sergei A Kharitonov, MD PhD", "affiliation": "Imperial College London", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Section of Airway Disease, Asthma Lab, Imperial College London, Royal Brompton Hospital", "city": "London", "country": "United Kingdom", "geoPoint": {"lat": 51.50853, "lon": -0.12574}}]}, "referencesModule": {"references": [{"pmid": "21903370", "type": "RESULT", "citation": "Essilfie-Quaye S, Ito K, Ito M, Kharitonov SA, Barnes PJ. Comparison of Symbicort(R) versus Pulmicort(R) on steroid pharmacodynamic markers in asthma patients. Respir Med. 2011 Dec;105(12):1784-9. doi: 10.1016/j.rmed.2011.08.020. Epub 2011 Sep 7."}]}, "ipdSharingStatementModule": {"ipdSharing": "NO"}}, "resultsSection": {"participantFlowModule": {"recruitmentDetails": "10patient recruited mild asthma", "groups": [{"id": "FG000", "title": "Placebo", "description": "first intervention is placebo, then Formoterol, then Budesonide low dose, then Budesonide high dose, then Budesonide/Formoterol single, then Budesonide/Formoterol double"}, {"id": "FG001", "title": "Formoterol", "description": "First intervention is formoterol, then placebo, then Budesonide low dose, then Budesonide high dose, then Budesonide/Formoterol single, then Budesonide/Formoterol double"}, {"id": "FG002", "title": "Budesonide Low Dose", "description": "First intervention is Budesonide low dose, then placebo, then Formoterol, then Budesonide high dose, then Budesonide/Formoterol single, then Budesonide/Formoterol double"}, {"id": "FG003", "title": "Budesonide High Dose", "description": "First intervention is Budesonide high dose, then placebo, then Formoterol, then Budesonide low dose, then Budesonide/Formoterol single, then Budesonide/Formoterol double"}, {"id": "FG004", "title": "Budesonide/Formoterol Single", "description": "First intervention is Budesonide/Formoterol single, then placebo, then Formoterol, then Budesonide low dose, then Budesonide high dose, then Budesonide/Formoterol double"}, {"id": "FG005", "title": "Budesonide/Formoterol Double", "description": "First intervention is Budesonide/Formoterol double, then placebo, then Formoterol, then Budesonide low dose, then Budesonide high dose, then Budesonide/Formoterol single"}], "periods": [{"title": "First Intervention", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "2"}, {"groupId": "FG003", "numSubjects": "2"}, {"groupId": "FG004", "numSubjects": "2"}, {"groupId": "FG005", "numSubjects": "2"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "2"}, {"groupId": "FG003", "numSubjects": "2"}, {"groupId": "FG004", "numSubjects": "2"}, {"groupId": "FG005", "numSubjects": "2"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}]}]}, {"title": "Washout", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "2"}, {"groupId": "FG003", "numSubjects": "2"}, {"groupId": "FG004", "numSubjects": "2"}, {"groupId": "FG005", "numSubjects": "2"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "2"}, {"groupId": "FG003", "numSubjects": "2"}, {"groupId": "FG004", "numSubjects": "2"}, {"groupId": "FG005", "numSubjects": "2"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}]}]}, {"title": "Second Intervention", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "2"}, {"groupId": "FG003", "numSubjects": "2"}, {"groupId": "FG004", "numSubjects": "2"}, {"groupId": "FG005", "numSubjects": "2"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "2"}, {"groupId": "FG003", "numSubjects": "2"}, {"groupId": "FG004", "numSubjects": "2"}, {"groupId": "FG005", "numSubjects": "2"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}]}]}, {"title": "Washout", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "2"}, {"groupId": "FG003", "numSubjects": "2"}, {"groupId": "FG004", "numSubjects": "2"}, {"groupId": "FG005", "numSubjects": "2"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "2"}, {"groupId": "FG003", "numSubjects": "2"}, {"groupId": "FG004", "numSubjects": "2"}, {"groupId": "FG005", "numSubjects": "2"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}]}]}, {"title": "Third Intervention", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "2"}, {"groupId": "FG003", "numSubjects": "2"}, {"groupId": "FG004", "numSubjects": "2"}, {"groupId": "FG005", "numSubjects": "2"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "2"}, {"groupId": "FG003", "numSubjects": "2"}, {"groupId": "FG004", "numSubjects": "2"}, {"groupId": "FG005", "numSubjects": "2"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}]}]}, {"title": "Washout", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "2"}, {"groupId": "FG003", "numSubjects": "2"}, {"groupId": "FG004", "numSubjects": "2"}, {"groupId": "FG005", "numSubjects": "2"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "2"}, {"groupId": "FG003", "numSubjects": "2"}, {"groupId": "FG004", "numSubjects": "2"}, {"groupId": "FG005", "numSubjects": "2"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}]}]}, {"title": "Fourth Intervention", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "2"}, {"groupId": "FG003", "numSubjects": "2"}, {"groupId": "FG004", "numSubjects": "2"}, {"groupId": "FG005", "numSubjects": "2"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "2"}, {"groupId": "FG003", "numSubjects": "2"}, {"groupId": "FG004", "numSubjects": "2"}, {"groupId": "FG005", "numSubjects": "2"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}]}]}, {"title": "Washout", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "2"}, {"groupId": "FG003", "numSubjects": "2"}, {"groupId": "FG004", "numSubjects": "2"}, {"groupId": "FG005", "numSubjects": "2"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "2"}, {"groupId": "FG003", "numSubjects": "2"}, {"groupId": "FG004", "numSubjects": "2"}, {"groupId": "FG005", "numSubjects": "2"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}]}]}, {"title": "Fifth Intervention", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "2"}, {"groupId": "FG003", "numSubjects": "2"}, {"groupId": "FG004", "numSubjects": "2"}, {"groupId": "FG005", "numSubjects": "2"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "2"}, {"groupId": "FG003", "numSubjects": "2"}, {"groupId": "FG004", "numSubjects": "2"}, {"groupId": "FG005", "numSubjects": "2"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}]}]}, {"title": "Washout", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "2"}, {"groupId": "FG003", "numSubjects": "2"}, {"groupId": "FG004", "numSubjects": "2"}, {"groupId": "FG005", "numSubjects": "2"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "2"}, {"groupId": "FG003", "numSubjects": "2"}, {"groupId": "FG004", "numSubjects": "2"}, {"groupId": "FG005", "numSubjects": "2"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}]}]}, {"title": "Sixth Intervention", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "2"}, {"groupId": "FG003", "numSubjects": "2"}, {"groupId": "FG004", "numSubjects": "2"}, {"groupId": "FG005", "numSubjects": "2"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "2"}, {"groupId": "FG003", "numSubjects": "2"}, {"groupId": "FG004", "numSubjects": "2"}, {"groupId": "FG005", "numSubjects": "2"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Overall Study", "description": "Crossover study, same volunteers in all arm, received the following interventions: formoterol, Budesonide low and high dose, or combination of these"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "10"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "10"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "33", "spread": "3"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "10"}]}], "categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "6"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "4"}]}]}]}, {"title": "Race and Ethnicity Not Collected", "populationDescription": "Race and Ethnicity were not collected from any participant.", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "0"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "United Kingdom", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "10"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "10"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Changes in GR-GRE Binding", "description": "The GR-GRE binding is the glucocorticoid receptor (GR) DNA binding affinity. GR-GRE activity as assed by enzyme-immunosorbent assay", "populationDescription": "Crossover, each patient had all treatments", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Inter-Quartile Range", "unitOfMeasure": "GRE activity (OD)", "timeFrame": "1-2h", "groups": [{"id": "OG000", "title": "Placebo", "description": "placebo\n\nPlacebos: Dry powder inhaler"}, {"id": "OG001", "title": "Formoterol", "description": "Oxis(\u00ae) 12 \u03bcg\n\nFormoterol Inhalant Powder: 12ug"}, {"id": "OG002", "title": "Budesonide Low Dose", "description": "Pulmicort(\u00ae) 200 \u03bcg\n\nBudesonide Powder: Inhaler"}, {"id": "OG003", "title": "Budesonide High Dose", "description": "Pulmicort(\u00ae) 800 \u03bcg\n\nBudesonide Powder: Inhaler"}, {"id": "OG004", "title": "Budesonide/Formoterol Combination Single", "description": "single 100/6 \u03bcg SYM100\n\nBudesonide and Formoterol Product: Combination Inhaler, Symbicort"}, {"id": "OG005", "title": "Budesonide/Formoterol Combination Double", "description": "double 200/12 \u03bcg SYM200\n\nBudesonide and Formoterol Product: Combination Inhaler, Symbicort"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "10"}, {"groupId": "OG001", "value": "10"}, {"groupId": "OG002", "value": "10"}, {"groupId": "OG003", "value": "10"}, {"groupId": "OG004", "value": "10"}, {"groupId": "OG005", "value": "10"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.4", "lowerLimit": "0.5", "upperLimit": "2"}, {"groupId": "OG001", "value": "1.4", "lowerLimit": "0.3", "upperLimit": "2.6"}, {"groupId": "OG002", "value": "1.6", "lowerLimit": "0.7", "upperLimit": "2.0"}, {"groupId": "OG003", "value": "2.3", "lowerLimit": "1.1", "upperLimit": "7"}, {"groupId": "OG004", "value": "3.5", "lowerLimit": "1.3", "upperLimit": "6.1"}, {"groupId": "OG005", "value": "3", "lowerLimit": "1.5", "upperLimit": "6"}]}]}], "analyses": [{"groupIds": ["OG000", "OG004"], "nonInferiorityType": "OTHER", "nonInferiorityComment": "Friedman ANOVA followed Dunn's pairwise comparisons", "pValue": "0.04", "statisticalMethod": "ANOVA"}]}, {"type": "PRIMARY", "title": "Changes in MKP-1 mRNA", "description": "Changes in MKP-1 mRNA measured by PCR", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Inter-Quartile Range", "unitOfMeasure": "MKP1/GNB2L1 ratio", "timeFrame": "1-2h", "groups": [{"id": "OG000", "title": "Placebo", "description": "placebo\n\nPlacebos: Dry powder inhaler"}, {"id": "OG001", "title": "Formoterol", "description": "Oxis(\u00ae) 12 \u03bcg\n\nFormoterol Inhalant Powder: 12ug"}, {"id": "OG002", "title": "Budesonide Low Dose", "description": "Pulmicort(\u00ae) 200 \u03bcg\n\nBudesonide Powder: Inhaler"}, {"id": "OG003", "title": "Budesonide High Dose", "description": "Pulmicort(\u00ae) 800 \u03bcg\n\nBudesonide Powder: Inhaler"}, {"id": "OG004", "title": "Budesonide/Formoterol Combination Single", "description": "single 100/6 \u03bcg SYM100\n\nBudesonide and Formoterol Product: Combination Inhaler, Symbicort"}, {"id": "OG005", "title": "Budesonide/Formoterol Combination Double", "description": "double 200/12 \u03bcg SYM200\n\nBudesonide and Formoterol Product: Combination Inhaler, Symbicort"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "10"}, {"groupId": "OG001", "value": "10"}, {"groupId": "OG002", "value": "10"}, {"groupId": "OG003", "value": "10"}, {"groupId": "OG004", "value": "10"}, {"groupId": "OG005", "value": "10"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1", "lowerLimit": "0.1", "upperLimit": "1"}, {"groupId": "OG001", "value": "3", "lowerLimit": "1", "upperLimit": "44"}, {"groupId": "OG002", "value": "3", "lowerLimit": "2", "upperLimit": "70"}, {"groupId": "OG003", "value": "4", "lowerLimit": "4", "upperLimit": "51"}, {"groupId": "OG004", "value": "5", "lowerLimit": "3", "upperLimit": "150"}, {"groupId": "OG005", "value": "5", "lowerLimit": "3", "upperLimit": "150"}]}]}], "analyses": [{"groupIds": ["OG000", "OG005"], "nonInferiorityType": "OTHER", "nonInferiorityComment": "Friedman Anova", "pValue": "0.01", "statisticalMethod": "ANOVA"}]}, {"type": "PRIMARY", "title": "IL8 mRNA", "description": "Measured by PCR", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Inter-Quartile Range", "unitOfMeasure": "IL8/GNB2L1 ratio", "timeFrame": "1-2h", "groups": [{"id": "OG000", "title": "Placebo", "description": "placebo\n\nPlacebos: Dry powder inhaler"}, {"id": "OG001", "title": "Formoterol", "description": "Oxis(\u00ae) 12 \u03bcg\n\nFormoterol Inhalant Powder: 12ug"}, {"id": "OG002", "title": "Budesonide Low Dose", "description": "Pulmicort(\u00ae) 200 \u03bcg\n\nBudesonide Powder: Inhaler"}, {"id": "OG003", "title": "Budesonide High Dose", "description": "Pulmicort(\u00ae) 800 \u03bcg\n\nBudesonide Powder: Inhaler"}, {"id": "OG004", "title": "Budesonide/Formoterol Combination Single", "description": "single 100/6 \u03bcg SYM100\n\nBudesonide and Formoterol Product: Combination Inhaler, Symbicort"}, {"id": "OG005", "title": "Budesonide/Formoterol Combination Double", "description": "double 200/12 \u03bcg SYM200\n\nBudesonide and Formoterol Product: Combination Inhaler, Symbicort"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "10"}, {"groupId": "OG001", "value": "10"}, {"groupId": "OG002", "value": "10"}, {"groupId": "OG003", "value": "10"}, {"groupId": "OG004", "value": "10"}, {"groupId": "OG005", "value": "10"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1", "lowerLimit": "0.1", "upperLimit": "1.7"}, {"groupId": "OG001", "value": "4", "lowerLimit": "0.1", "upperLimit": "20"}, {"groupId": "OG002", "value": "4", "lowerLimit": "0.1", "upperLimit": "20"}, {"groupId": "OG003", "value": "0.4", "lowerLimit": "0.1", "upperLimit": "1.3"}, {"groupId": "OG004", "value": "0.2", "lowerLimit": "0.1", "upperLimit": "0.7"}, {"groupId": "OG005", "value": "0.2", "lowerLimit": "0.1", "upperLimit": "1.4"}]}]}], "analyses": [{"groupIds": ["OG000", "OG005"], "nonInferiorityType": "OTHER", "nonInferiorityComment": "Friedman Anova", "pValue": "0.04", "statisticalMethod": "ANOVA"}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "1 year", "eventGroups": [{"id": "EG000", "title": "Placebo", "description": "Patients who received placebo treatment", "deathsNumAffected": 0, "deathsNumAtRisk": 10, "seriousNumAffected": 0, "seriousNumAtRisk": 10, "otherNumAffected": 0, "otherNumAtRisk": 10}, {"id": "EG001", "title": "Formoterol", "description": "Patients who received Formoterol treatment", "deathsNumAffected": 0, "deathsNumAtRisk": 10, "seriousNumAffected": 0, "seriousNumAtRisk": 10, "otherNumAffected": 0, "otherNumAtRisk": 10}, {"id": "EG002", "title": "Budesonide Low Dose", "description": "Patients who received Budesonide low dose treatment", "deathsNumAffected": 0, "deathsNumAtRisk": 10, "seriousNumAffected": 0, "seriousNumAtRisk": 10, "otherNumAffected": 0, "otherNumAtRisk": 10}, {"id": "EG003", "title": "Budesonide High Dose", "description": "Patients who received Budesonide high dose treatment", "deathsNumAffected": 0, "deathsNumAtRisk": 10, "seriousNumAffected": 0, "seriousNumAtRisk": 10, "otherNumAffected": 0, "otherNumAtRisk": 10}, {"id": "EG004", "title": "Budesonide/Formoterol Single", "description": "Patients who received Budesonide/Formoterol single dose treatment", "deathsNumAffected": 0, "deathsNumAtRisk": 10, "seriousNumAffected": 0, "seriousNumAtRisk": 10, "otherNumAffected": 0, "otherNumAtRisk": 10}, {"id": "EG005", "title": "Budesonide/Formoterol Double", "description": "Patients who received Budesonide/Formoterol double dose treatment", "deathsNumAffected": 0, "deathsNumAtRisk": 10, "seriousNumAffected": 0, "seriousNumAtRisk": 10, "otherNumAffected": 0, "otherNumAtRisk": 10}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": true}, "pointOfContact": {"title": "Peter Barnes", "organization": "Imperial College London", "email": "p.j.barnes@imperial.ac.uk", "phone": "+44 (0)20 7594 7959"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M27137", "name": "Respiratory Aspiration", "relevance": "LOW"}, {"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC20", "name": "Immune System Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000019819", "term": "Budesonide"}, {"id": "D000068759", "term": "Formoterol Fumarate"}, {"id": "D000069502", "term": "Budesonide, Formoterol Fumarate Drug Combination"}], "ancestors": [{"id": "D000000893", "term": "Anti-Inflammatory Agents"}, {"id": "D000001993", "term": "Bronchodilator Agents"}, {"id": "D000001337", "term": "Autonomic Agents"}, {"id": "D000018373", "term": "Peripheral Nervous System Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}, {"id": "D000005938", "term": "Glucocorticoids"}, {"id": "D000006728", "term": "Hormones"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D000058666", "term": "Adrenergic beta-2 Receptor Agonists"}, {"id": "D000000318", "term": "Adrenergic beta-Agonists"}, {"id": "D000000322", "term": "Adrenergic Agonists"}, {"id": "D000018663", "term": "Adrenergic Agents"}, {"id": "D000018377", "term": "Neurotransmitter Agents"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M21711", "name": "Budesonide", "asFound": "Of 1", "relevance": "HIGH"}, {"id": "M9047", "name": "Glucocorticoids", "relevance": "LOW"}, {"id": "M304", "name": "Formoterol Fumarate", "asFound": "Nicotine", "relevance": "HIGH"}, {"id": "M452", "name": "Budesonide, Formoterol Fumarate Drug Combination", "asFound": "Early Stage", "relevance": "HIGH"}, {"id": "M4217", "name": "Anti-Inflammatory Agents", "relevance": "LOW"}, {"id": "M5269", "name": "Bronchodilator Agents", "relevance": "LOW"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}, {"id": "M20746", "name": "Adrenergic Agents", "relevance": "LOW"}, {"id": "M3670", "name": "Adrenergic beta-Agonists", "relevance": "LOW"}, {"id": "M3673", "name": "Adrenergic Agonists", "relevance": "LOW"}, {"id": "M20504", "name": "Neurotransmitter Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Infl", "name": "Anti-Inflammatory Agents"}, {"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}